← Back to Search

CAR T-cell Therapy

MultiTAA-Specific T Cells for Acute Lymphoblastic Leukemia (STELLA Trial)

Phase 1
Waitlist Available
Led By Bilal Omer, MD
Research Sponsored by Baylor College of Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Minimal residual disease (MRD) defined as detection in blood or marrow of leukemia-specific marker, leukemia-specific phenotype, or mixed donor chimerism
Available donor-derived multiTAA-specific T cell line
Must not have
Evidence of GVHD greater than Grade II
Severe intercurrent infection
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Summary

This trial is testing a new treatment for leukemia that uses special blood cells to target proteins specific to the cancer.

Who is the study for?
This trial is for patients with Acute Lymphoblastic Leukemia (ALL) who have undergone a stem cell transplant but still face the risk of cancer returning or not responding to treatment. Eligible participants must have a life expectancy of at least 6 weeks, stable vital signs, and an available donor-derived T cell line. They should be treated within specific hospitals in Texas and agree to use effective birth control post-treatment.Check my eligibility
What is being tested?
The study tests whether special blood cells called multiTAA-specific T cells can target and kill leukemia cells after being infused into patients post-stem cell transplant. These T cells are trained to recognize certain proteins found on most ALL cancer cells, aiming to find the highest safe dose for these patients.See study design
What are the potential side effects?
Potential side effects aren't specified in this summary, but similar treatments often involve immune reactions, fatigue, fever, chills or risks associated with infusions such as infection at the injection site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My tests show minimal signs of leukemia in my blood or bone marrow.
Select...
I have access to a specific T cell line treatment.
Select...
My cancer returned or remained after a transplant, confirmed by tests.
Select...
I am scheduled for a stem cell transplant at CAGT.
Select...
I will get my treatment at Texas Children's or Houston Methodist Hospital.
Select...
I am able to live with some level of independence.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a complication from a transplant that is moderate to severe.
Select...
I am currently suffering from a severe infection.
Select...
I am currently on a high dose of corticosteroids.
Select...
I had a stem cell transplant from a donor less than 30 days ago.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of patients with dose-limiting toxicities (DLTs).
Secondary outcome measures
Median number of T cells post-infusion.
Number of patients with a decrease in the marker of disease.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Group BExperimental Treatment1 Intervention
Treatment with donor-derived multiTAA-specific T cells for relapsed/residual disease following HSCT for ALL.
Group II: Group AExperimental Treatment1 Intervention
Treatment with donor-derived multiTAA-specific T cells as adjuvant therapy following HSCT for ALL.

Find a Location

Who is running the clinical trial?

Center for Cell and Gene Therapy, Baylor College of MedicineOTHER
111 Previous Clinical Trials
2,783 Total Patients Enrolled
The Methodist Hospital Research InstituteOTHER
275 Previous Clinical Trials
80,497 Total Patients Enrolled
Baylor College of MedicineLead Sponsor
1,006 Previous Clinical Trials
6,003,268 Total Patients Enrolled

Media Library

MultiTAA-specific T cells (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT02475707 — Phase 1
Acute Lymphoblastic Leukemia Research Study Groups: Group A, Group B
Acute Lymphoblastic Leukemia Clinical Trial 2023: MultiTAA-specific T cells Highlights & Side Effects. Trial Name: NCT02475707 — Phase 1
MultiTAA-specific T cells (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02475707 — Phase 1
~4 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top